Cargando…

The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study

BACKGROUND: Immortal time bias (ITB) has been overlooked in idiopathic pulmonary fibrosis (IPF). We aimed to identify the presence of ITB in observational studies examining associations between antifibrotic therapy and survival in patients with IPF and illustrate how ITB may affect effect size estim...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Qiang, Otahal, Petr, Cox, Ingrid A., de Graaff, Barbara, Campbell, Julie A., Ahmad, Hasnat, Walters, E. Haydn, Palmer, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126672/
https://www.ncbi.nlm.nih.gov/pubmed/37113607
http://dx.doi.org/10.3389/fmed.2023.1157706
_version_ 1785030307140861952
author Zheng, Qiang
Otahal, Petr
Cox, Ingrid A.
de Graaff, Barbara
Campbell, Julie A.
Ahmad, Hasnat
Walters, E. Haydn
Palmer, Andrew J.
author_facet Zheng, Qiang
Otahal, Petr
Cox, Ingrid A.
de Graaff, Barbara
Campbell, Julie A.
Ahmad, Hasnat
Walters, E. Haydn
Palmer, Andrew J.
author_sort Zheng, Qiang
collection PubMed
description BACKGROUND: Immortal time bias (ITB) has been overlooked in idiopathic pulmonary fibrosis (IPF). We aimed to identify the presence of ITB in observational studies examining associations between antifibrotic therapy and survival in patients with IPF and illustrate how ITB may affect effect size estimates of those associations. METHODS: Immortal time bias was identified in observational studies using the ITB Study Assessment Checklist. We used a simulation study to illustrate how ITB may affect effect size estimates of antifibrotic therapy on survival in patients with IPF based on four statistical techniques including time-fixed, exclusion, time-dependent and landmark methods. RESULTS: Of the 16 included IPF studies, ITB was detected in 14 studies, while there were insufficient data for assessment in two others. Our simulation study showed that use of time–fixed [hazard ratio (HR) 0.55, 95% confidence interval (CI) 0.47–0.64] and exclusion methods (HR 0.79, 95% CI 0.67–0.92) overestimated the effectiveness of antifibrotic therapy on survival in simulated subjects with IPF, in comparison of the time–dependent method (HR 0.93, 95% CI 0.79–1.09). The influence of ITB was mitigated using the 1 year landmark method (HR 0.69, 95% CI 0.58–0.81), compared to the time–fixed method. CONCLUSION: The effectiveness of antifibrotic therapy on survival in IPF can be overestimated in observational studies, if ITB is mishandled. This study adds to the evidence for addressing the influence of ITB in IPF and provides several recommendations to minimize ITB. Identifying the presence of ITB should be routinely considered in future IPF studies, with the time–dependent method being an optimal approach to minimize ITB.
format Online
Article
Text
id pubmed-10126672
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-101266722023-04-26 The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study Zheng, Qiang Otahal, Petr Cox, Ingrid A. de Graaff, Barbara Campbell, Julie A. Ahmad, Hasnat Walters, E. Haydn Palmer, Andrew J. Front Med (Lausanne) Medicine BACKGROUND: Immortal time bias (ITB) has been overlooked in idiopathic pulmonary fibrosis (IPF). We aimed to identify the presence of ITB in observational studies examining associations between antifibrotic therapy and survival in patients with IPF and illustrate how ITB may affect effect size estimates of those associations. METHODS: Immortal time bias was identified in observational studies using the ITB Study Assessment Checklist. We used a simulation study to illustrate how ITB may affect effect size estimates of antifibrotic therapy on survival in patients with IPF based on four statistical techniques including time-fixed, exclusion, time-dependent and landmark methods. RESULTS: Of the 16 included IPF studies, ITB was detected in 14 studies, while there were insufficient data for assessment in two others. Our simulation study showed that use of time–fixed [hazard ratio (HR) 0.55, 95% confidence interval (CI) 0.47–0.64] and exclusion methods (HR 0.79, 95% CI 0.67–0.92) overestimated the effectiveness of antifibrotic therapy on survival in simulated subjects with IPF, in comparison of the time–dependent method (HR 0.93, 95% CI 0.79–1.09). The influence of ITB was mitigated using the 1 year landmark method (HR 0.69, 95% CI 0.58–0.81), compared to the time–fixed method. CONCLUSION: The effectiveness of antifibrotic therapy on survival in IPF can be overestimated in observational studies, if ITB is mishandled. This study adds to the evidence for addressing the influence of ITB in IPF and provides several recommendations to minimize ITB. Identifying the presence of ITB should be routinely considered in future IPF studies, with the time–dependent method being an optimal approach to minimize ITB. Frontiers Media S.A. 2023-04-11 /pmc/articles/PMC10126672/ /pubmed/37113607 http://dx.doi.org/10.3389/fmed.2023.1157706 Text en Copyright © 2023 Zheng, Otahal, Cox, de Graaff, Campbell, Ahmad, Walters and Palmer. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Zheng, Qiang
Otahal, Petr
Cox, Ingrid A.
de Graaff, Barbara
Campbell, Julie A.
Ahmad, Hasnat
Walters, E. Haydn
Palmer, Andrew J.
The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study
title The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study
title_full The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study
title_fullStr The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study
title_full_unstemmed The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study
title_short The influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: A simulation study
title_sort influence of immortal time bias in observational studies examining associations of antifibrotic therapy with survival in idiopathic pulmonary fibrosis: a simulation study
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10126672/
https://www.ncbi.nlm.nih.gov/pubmed/37113607
http://dx.doi.org/10.3389/fmed.2023.1157706
work_keys_str_mv AT zhengqiang theinfluenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT otahalpetr theinfluenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT coxingrida theinfluenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT degraaffbarbara theinfluenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT campbelljuliea theinfluenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT ahmadhasnat theinfluenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT waltersehaydn theinfluenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT palmerandrewj theinfluenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT zhengqiang influenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT otahalpetr influenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT coxingrida influenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT degraaffbarbara influenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT campbelljuliea influenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT ahmadhasnat influenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT waltersehaydn influenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy
AT palmerandrewj influenceofimmortaltimebiasinobservationalstudiesexaminingassociationsofantifibrotictherapywithsurvivalinidiopathicpulmonaryfibrosisasimulationstudy